Observes outcomes in people with sudden worsening pulmonary hypertension across Europe
Follows people with sudden worsening pulmonary hypertension, recording clinical, blood and heart scan data.
Plain-language title generated from the registry record
Registry title: European Registry of Acutely Decompensated Pulmonary Arterial Hypertension
Key facts
- Where
- Le Kremlin-Bicetre, FranceSee the site
Where in France
- Assistance Publique Hopitaux De ParisLe Kremlin-Bicetre, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Trial code
- NCT06923917
- Record updated
- 24 November 2025
- Original description
Acute decompensation of pulmonary hypertension (PH) is associated with a very unfavorable short-term prognosis. However, the development of circulatory support techniques and the possible use of emergency transplantation in recent years has significantly changed the management of patients with refractory right ventricular failure. Nonetheless, there are significant disparities in the management of these patients depending on the organization of the care pathway, the rules for graft allocation, and access to circulatory support across European countries. Moreover, the implementation of these new therapeutic strategies requires the identification of effective prognostic factors and the development of new monitoring techniques. The objective of this collaborative clinical research project is to study the prognostic implications of acute decompensated right heart failure associated with PAH based on a large-scale European multicenter approach using a prospective analysis of clinical, biological, and echocardiographic data.Read full original descriptionShow less
European Registry of Acutely Decompensated Pulmonary Hypertension
Acute decompensation of pulmonary hypertension (PH) is associated with a very unfavorable short-term prognosis. However, the development of circulatory support techniques and the possible use of emergency transplantation in recent years has significantly changed the management of patients with refractory right ventricular failure. Nonetheless, there are significant disparities in the management of these patients depending on the organization of the care pathway, the rules for graft allocation, and access to circulatory support across European countries. Moreover, the implementation of these new therapeutic strategies requires the identification of effective prognostic factors and the development of new monitoring techniques. The objective of this collaborative clinical research project is to study the prognostic implications of acute decompensated right heart failure associated with PAH based on a large-scale European multicenter approach using a prospective analysis of clinical, biological, and echocardiographic data.
Inclusion: Patients with established diagnosis of pulmonary arterial hypertension (group 1) according to the 2022 ESC/ERS guidelines; Worsening of clinical signs of right heart failure in the month prior to hospital admission requiring the use of:; intravenous diuretic therapy for ≥ 2 days; or inotropes; or vasopressors.
Exclusion: Patients with non-group 1 pulmonary hypertension; Shock due to a cause other than right heart failure; Person under psychiatric care; Person unable to provide written informed consent (person deprived of liberty by judicial or administrative decision); Person who is the subject of a legal protection measure (tutelage, guardianship, safeguard of justice); Patient's objection to the use of their data.